Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 13/20 | 0.48 |
| ▸ | NOS1 | P29475 | 13/20 | 0.48 |
| ▸ | NOS2 | P35228 | 8/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833425 | 0.82 | NOS1 (0.66) | NOS3NOS1NOS2HTR2ACHRM2 | |
| SCHEMBL6617583 | 0.80 | NOS1 (0.71) | NOS3NOS1BACE1KDM4ECYP1A2 | |
| SCHEMBL5833939 | 0.76 | NOS1 (0.52) | NOS3NOS1NOS2CHRM2CHRM4 | |
| SCHEMBL8314311 | 0.72 | NOS1 (0.60) | NOS3NOS1BACE1KDM4ECYP1A2 | |
| SCHEMBL5833626 | 0.70 | NOS1 (0.69) | NOS3NOS1NOS2TSHRCHRM2 | |
| SCHEMBL5833899 | 0.69 | ABCB1 (0.54) | NOS3NOS1NOS2 | |
| SCHEMBL7754129 | 0.68 | CARM1 (0.55) | BACE1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5833259 | 0.67 | NOS3 (0.75) | NOS3NOS1NOS2 | |
| SCHEMBL5833437 | 0.67 | NOS1 (0.78) | NOS3NOS1NOS2HTR2ACHRM2 | |
| SCHEMBL6619732 | 0.66 | NOS1 (0.50) | NOS3NOS1NOS2HTR2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012078-B2 | 2-aminopyridines containing fused ring substituents | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1007520-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PROD INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN ADAMS (US) | 2001-12-06 | — | — | US | disclosed |
| EP-1007520-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010339-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885NOS2 1/4885 |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885NOS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.